Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal CRJIM (Clinical and Research Journal in Internal Medicine)
Nasution, Muhammad Imanuddin
Unknown Affiliation
Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Comparison of HBV DNA Quantitative Log in Patients Hepatitis B with Telbivudine Therapy Compared with Tenofovir Therapy in Saiful Anwar General Hospital Malang: January 2016 - December 2017 Nasution, Muhammad Imanuddin; Mustika, Syifa
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.5

Abstract

Background: Hepatitis B is a health problem with high endemic in Indonesia. Hepatitis B virus infection is transmitted parenterally, has a risk of liver cirrhosis and hepatocellular carcinoma. Detection and quantification of HBV DNA are markers of active HBV replication and determine treatment options for hepatitis B. Methods: compare log reduction of HBV DNA in patients treated with Telbivudine and Tenofovir. Results: There was no significant difference in HBV DNA levels between before and after Tenofovir treatment, namely 6 months follow-up (OR 95% CI = 5.41 [0.83 - 35.16], p = 0.0770) and 12 months (OR 95% CI = 5.39 [0.83 - 34.99], p = 0.0780). Telbivudine administration showed a significant difference in HBV DNA levels between before and after treatment at 6 months follow-up (OR 95% CI = 13.69 [4.53 - 41.40], p = 0.0001) and 12 months (OR 95% CI = 13.69 [ 4.53 - 41.41], p = 0.0001). Comparison of Tenofovir and Telbivudine therapy showed no significant difference at 6 months follow-up (OR 95% CI = 0.44 [0.10 - 1.88], p = 0.2690) but significant at 12 months follow-up (OR 95% CI = 6.23). [1.39 - 27.97], p = 0.0170). Conclusion:  There was a significant difference between the administration of Telbivudine as a treatment for hepatitis B with lower serum HBV DNA levels compared with the administration of Tenofovir at 12-month follow-up therapy.
Co-Authors Syifa Mustika